Medifast Inc · NYSE:MED
Medifast — Q2 2026 Earnings Presentation
13 slides from Medifast's earnings presentation, Aug 3, 2026
Slide 1: Q2 2026 Earning Supplement
Q2 2026 Earning Supplement © 2026 Medifast, Inc. All Rights Reserved. 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking s
Slide 3: Medifast Q2 2026 Highlights
Medifast® Q2 2026 Highlights Revenue within Guidance Range, EPS above Guidance Range Gross Profit Margin of 69.9% was down 270 bp versus Q2 2025, impacted by loss of leverage of fixed costs Operating Income declined versus Q2 2025, negatively impacted by loss of leverage of fixed costs partially off
Slide 4: Q2 2026 – By the Numbers
| Q2 2026 – By the Numbers $76M $160M ($0.28) revenue working capital loss per share $6,529 11,700 $170M revenue per active active earning cash & cash equivalents earning coach coaches and investments © 2026 Medifast, Inc. All Rights Reserved. 4
Slide 5: Early Signals of Business Improvement
Early Signals of Business Improvement Coach Productivity • Q2 coach productivity gain of 41% Y/Y & 20% Q/Q § Third consecutive quarter of growth • Highest revenue per AEC since Q2 2022 § Expected to continue to rise throughout 2026 Productivity Improvements Historically Precede Coach & Revenue Growt
Slide 6: Going Beyond Weight Loss
Going Beyond Weight Loss Science-Driven Innovation Coaches at the Center Enhanced Business Model • 45+ years of scientific heritage • Human connection is core to approach • A 10-year plan through 2036 to drive innovation and advance optimal health • Once-in-a-generation opportunity to • Coaches tran
Slide 7: New Brand
New Brand: • Brand reflects the broader metabolic focus of the business • A name built for where the company is going, not where it has been - a modern metabolic health company for today’s and tomorrow’s opportunities • A metabolic health system across 3 phases - reset, refine, & renew • Positions b
Slide 8: Medifast's Breakthrough Scientific Framework
Metabolic Synchronization®: Medifast’s Breakthrough Scientific Framework Metabolic Synchronization Outcomes Targets the root of metabolic dysfunction to Delivers strong & targeted fat burn, creating improve metabolic health beyond weight loss conditions for improvement in body composition, • Systema
Slide 9: Medifast Metabolic Health Institute Core Pillars: Optimal Metabolic Health
Medifast Metabolic Health Institute™ Core Pillars: Optimal Metabolic Health Through the Medifast Metabolic Health Institute™, the company is: Elevating the importance of metabolic health as a cornerstone of well-being Metabolic Metabolic Products Research Health Health & Development Science Research
Slide 10: Enhanced Product Line Ready to Launch
Enhanced Product Line Ready to Launch: Upgraded for Optimal Metabolic Health Now With The New MetaVantage Nutrition Blueprint Technology™ Nutrient-dense Clinically studied postbiotic High-quality helps support a reduced complete protein waist circumference* Interchangeable + Chromium picolinate 24 e
Slide 11: Strong Feedback From Product Pilot Program Participants
Strong Feedback From Product Pilot Program 33 Participants successfully completed the 12-week program On average, participants lost 21.6 lbs.* On average, participants reduced their visceral fat** score by 2.4 pts. *Average weight loss on the Reset 5 & 1 Plan is 12 pounds. Clients are in weight loss
Slide 12: Building for Sustainable Growth
Looking Ahead Building for Sustainable Growth Consistent & Clear Strategy Science-based, coach-guided system, executing a 10-year roadmap to help people achieve long-term metabolic health New Brand & Products • OPTAVIA® has become TrilivyTM — a metabolic health system across three phases: reset, ref
Slide 13: 2026 – Guidance
| 2026 – Guidance Q3 2026 $60M - $80M ($0.15) – ($0.65) Q3 revenue Q3 loss per share FY 2026 $270M - $300M ($0.25) – ($1.75) FY revenue FY loss per share © 2026 Medifast, Inc. All Rights Reserved. 13